B

Biomedica Research Group | Santiago, Chile

Research site
(Unclaimed)
Location
Av. Salvador 149 Oficina 1101, Santiago, Santiago, Chile

Site insights

Top conditions

Top treatments

Litifilimab
BIIB059
Gantenerumab
Etrasimod
Pimavanserin
Iclepertin
Deucravacitinib
PF-05212377
mRNA-1345
Seltorexant

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 27 total trials

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis (GALARISSO)

The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered...

Enrolling
Dermatomyositis
Drug: Placebo
Drug: GLPG3667

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling
Atrial Fibrillation
Drug: Placebo
Drug: Apixaban Placebo
Locations recently updated

The primary objectives of the study are to evaluate the efficacy of BIIB059 (litifilimab) compared with placebo in reducing skin disease activity mea...

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: BIIB059 (litifilimab)
Drug: Placebo

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling
Systemic Lupus Erythematosus
Drug: Deucravacitinib
Other: Placebo
Locations recently updated

The primary objective of this study is to evaluate the long-term safety and tolerability of litifilimab in participants with active systemic lupus er...

Invitation-only
Systemic Lupus Erythematosus (SLE)
Drug: Litifilimab-matching placebo
Drug: Litifilimab

The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.

Enrolling
Sjögren's Syndrome
Other: Placebo
Drug: Deucravacitinib

The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single...

Active, not recruiting
Respiratory Syncytial Virus
Drug: Placebo
Drug: mRNA-1345

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Enrolling
Lupus Erythematosus, Systemic
Drug: Litifilimab
Drug: Placebo

This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of t...

Enrolling
Schizophrenia
Drug: Iclepertin

This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Example...

Active, not recruiting
Schizophrenia
Drug: Placebo
Drug: Iclepertin

Trial sponsors

Pfizer logo
Biogen logo
Roche logo
Acadia Pharmaceuticals logo
A
Boehringer Ingelheim logo
Bristol-Myers Squibb (BMS) logo
J
G
G

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems